Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Apellis Pharmaceuticals, Inc. related to misrepresentations regarding the clinical trials of SYFOVRE [1] Group 1: Legal Investigation - A federal securities lawsuit claims that Apellis insiders misrepresented the design of SYFOVRE's clinical trials, which was inadequate to identify retinal vasculitis incidents in patients [1] - The lawsuit indicates that the commercial adoption of SYFOVRE is subject to significant unknown risk factors due to these misrepresentations [1] - Consequently, statements made by the company regarding its business, operations, and prospects are deemed to lack a reasonable basis [1] Group 2: Shareholder Information - Shareholders who purchased Apellis stock prior to January 28, 2021 are encouraged to contact Kuehn Law for a free consultation regarding their rights [2] - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of timely action for shareholders [2] Group 3: Importance of Participation - The involvement of shareholders is highlighted as crucial for maintaining the integrity and fairness of financial markets, reinforcing the idea that every investment and voice matters [3]